Association Between New-Onset Proteinuria During Hospitalization and Cardiovascular Mortality Among Patients With Atherosclerotic Cardiovascular Disease

Figures

• 

  Figure 1. Flowchart of the Study 34,429 participants were included. ASCVD = atherosclerotic cardiovascular disease; CRDS = China Renal Data System; eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease.

• 

  Figure 2. Cumulative Incidence of Cardiovascular Mortality and Composite Kidney Outcomes Kaplan-Meier (KM) method was employed. (A) P < 0.0001 for cardiovascular mortality aaand (B) P = 0.00036 for composite kidney outcomes.

• 

  Figure 3. Subgroup Analyses ∗HR were adjusted for age, sex, BMI, SBP, DBP, eGFR, hemoglobin, LDL-C, serum albumin, urine specific gravity, Charlson Comorbidity Index, comorbidities, and co-medications. Possible effect modification was examined by introducing multiplicative interaction terms between new-onset proteinuria and the potential effect modifiers into our Cox regression model. ACS = acute coronary syndrome; RASi = renin angiotensin system inhibitor.

• 

  Central Illustration. The Association of New-Onset Proteinuria Cardiovascular Mortality ∗HR were adjusted for age, sex, BMI, SBP, DBP, eGFR, hemoglobin, LDL-C, serum albumin, urine specific gravity, Charlson Comorbidity Index, comorbidities, and co-medications. Possible effect modification was examined by introducing multiplicative interaction terms between new-onset proteinuria and the potential effect modifiers into our Cox regression model. ACS = acute coronary syndrome; RASi = Renin Angiotensin System inhibitor.